Free Trial

Danaher (DHR) Competitors

Danaher logo
$175.20 +1.16 (+0.67%)
As of 03:05 PM Eastern
This is a fair market value price provided by Massive. Learn more.

DHR vs. RGEN, TECH, A, CR, and CSL

Should you be buying Danaher stock or one of its competitors? The main competitors of Danaher include Repligen (RGEN), Bio-Techne (TECH), Agilent Technologies (A), Crane (CR), and Carlisle Companies (CSL).

How does Danaher compare to Repligen?

Repligen (NASDAQ:RGEN) and Danaher (NYSE:DHR) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, institutional ownership, valuation, dividends, analyst recommendations and media sentiment.

In the previous week, Danaher had 14 more articles in the media than Repligen. MarketBeat recorded 30 mentions for Danaher and 16 mentions for Repligen. Danaher's average media sentiment score of 1.07 beat Repligen's score of 0.66 indicating that Danaher is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Repligen
8 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive
Danaher
21 Very Positive mention(s)
4 Positive mention(s)
1 Neutral mention(s)
2 Negative mention(s)
2 Very Negative mention(s)
Positive

97.6% of Repligen shares are owned by institutional investors. Comparatively, 79.1% of Danaher shares are owned by institutional investors. 0.6% of Repligen shares are owned by insiders. Comparatively, 10.8% of Danaher shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Danaher has a net margin of 14.89% compared to Repligen's net margin of 6.62%. Danaher's return on equity of 10.91% beat Repligen's return on equity.

Company Net Margins Return on Equity Return on Assets
Repligen6.62% 4.71% 3.34%
Danaher 14.89%10.91%6.94%

Repligen currently has a consensus target price of $170.25, suggesting a potential upside of 35.00%. Danaher has a consensus target price of $240.70, suggesting a potential upside of 37.31%. Given Danaher's higher probable upside, analysts clearly believe Danaher is more favorable than Repligen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Repligen
1 Sell rating(s)
2 Hold rating(s)
9 Buy rating(s)
2 Strong Buy rating(s)
2.86
Danaher
0 Sell rating(s)
3 Hold rating(s)
18 Buy rating(s)
0 Strong Buy rating(s)
2.86

Danaher has higher revenue and earnings than Repligen. Danaher is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Repligen$738.26M9.63$48.89M$0.85148.37
Danaher$24.78B5.01$3.61B$5.1733.91

Repligen has a beta of 1.09, indicating that its share price is 9% more volatile than the S&P 500. Comparatively, Danaher has a beta of 0.81, indicating that its share price is 19% less volatile than the S&P 500.

Summary

Danaher beats Repligen on 11 of the 16 factors compared between the two stocks.

How does Danaher compare to Bio-Techne?

Bio-Techne (NASDAQ:TECH) and Danaher (NYSE:DHR) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership, analyst recommendations and media sentiment.

98.9% of Bio-Techne shares are owned by institutional investors. Comparatively, 79.1% of Danaher shares are owned by institutional investors. 1.3% of Bio-Techne shares are owned by company insiders. Comparatively, 10.8% of Danaher shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Bio-Techne pays an annual dividend of $0.32 per share and has a dividend yield of 0.6%. Danaher pays an annual dividend of $1.60 per share and has a dividend yield of 0.9%. Bio-Techne pays out 62.7% of its earnings in the form of a dividend. Danaher pays out 30.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Danaher has increased its dividend for 2 consecutive years. Danaher is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Danaher has a net margin of 14.89% compared to Bio-Techne's net margin of 6.67%. Bio-Techne's return on equity of 13.94% beat Danaher's return on equity.

Company Net Margins Return on Equity Return on Assets
Bio-Techne6.67% 13.94% 10.76%
Danaher 14.89%10.91%6.94%

Bio-Techne has a beta of 1.41, indicating that its share price is 41% more volatile than the S&P 500. Comparatively, Danaher has a beta of 0.81, indicating that its share price is 19% less volatile than the S&P 500.

In the previous week, Danaher had 23 more articles in the media than Bio-Techne. MarketBeat recorded 30 mentions for Danaher and 7 mentions for Bio-Techne. Bio-Techne's average media sentiment score of 1.20 beat Danaher's score of 1.07 indicating that Bio-Techne is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Bio-Techne
4 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Danaher
21 Very Positive mention(s)
4 Positive mention(s)
1 Neutral mention(s)
2 Negative mention(s)
2 Very Negative mention(s)
Positive

Danaher has higher revenue and earnings than Bio-Techne. Danaher is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bio-Techne$1.22B7.28$73.40M$0.51110.97
Danaher$24.78B5.01$3.61B$5.1733.91

Bio-Techne currently has a consensus target price of $72.77, suggesting a potential upside of 28.58%. Danaher has a consensus target price of $240.70, suggesting a potential upside of 37.31%. Given Danaher's stronger consensus rating and higher probable upside, analysts clearly believe Danaher is more favorable than Bio-Techne.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bio-Techne
1 Sell rating(s)
3 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.71
Danaher
0 Sell rating(s)
3 Hold rating(s)
18 Buy rating(s)
0 Strong Buy rating(s)
2.86

Summary

Danaher beats Bio-Techne on 12 of the 20 factors compared between the two stocks.

How does Danaher compare to Agilent Technologies?

Danaher (NYSE:DHR) and Agilent Technologies (NYSE:A) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, institutional ownership, valuation, analyst recommendations, risk and media sentiment.

Agilent Technologies has a net margin of 18.26% compared to Danaher's net margin of 14.89%. Agilent Technologies' return on equity of 24.49% beat Danaher's return on equity.

Company Net Margins Return on Equity Return on Assets
Danaher14.89% 10.91% 6.94%
Agilent Technologies 18.26%24.49%12.83%

In the previous week, Danaher had 19 more articles in the media than Agilent Technologies. MarketBeat recorded 30 mentions for Danaher and 11 mentions for Agilent Technologies. Danaher's average media sentiment score of 1.07 beat Agilent Technologies' score of 0.97 indicating that Danaher is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Danaher
21 Very Positive mention(s)
4 Positive mention(s)
1 Neutral mention(s)
2 Negative mention(s)
2 Very Negative mention(s)
Positive
Agilent Technologies
6 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Danaher has higher revenue and earnings than Agilent Technologies. Agilent Technologies is trading at a lower price-to-earnings ratio than Danaher, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Danaher$24.78B5.01$3.61B$5.1733.91
Agilent Technologies$6.95B4.77$1.30B$4.5325.91

79.1% of Danaher shares are owned by institutional investors. 10.8% of Danaher shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Danaher has a beta of 0.81, suggesting that its share price is 19% less volatile than the S&P 500. Comparatively, Agilent Technologies has a beta of 1.22, suggesting that its share price is 22% more volatile than the S&P 500.

Danaher presently has a consensus target price of $240.70, suggesting a potential upside of 37.31%. Agilent Technologies has a consensus target price of $163.71, suggesting a potential upside of 39.48%. Given Agilent Technologies' stronger consensus rating and higher possible upside, analysts plainly believe Agilent Technologies is more favorable than Danaher.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Danaher
0 Sell rating(s)
3 Hold rating(s)
18 Buy rating(s)
0 Strong Buy rating(s)
2.86
Agilent Technologies
0 Sell rating(s)
2 Hold rating(s)
11 Buy rating(s)
2 Strong Buy rating(s)
3.00

Danaher pays an annual dividend of $1.60 per share and has a dividend yield of 0.9%. Agilent Technologies pays an annual dividend of $1.02 per share and has a dividend yield of 0.9%. Danaher pays out 30.9% of its earnings in the form of a dividend. Agilent Technologies pays out 22.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Danaher has increased its dividend for 2 consecutive years and Agilent Technologies has increased its dividend for 9 consecutive years.

Summary

Danaher beats Agilent Technologies on 11 of the 20 factors compared between the two stocks.

How does Danaher compare to Crane?

Danaher (NYSE:DHR) and Crane (NYSE:CR) are related large-cap companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, dividends, risk, profitability, analyst recommendations, media sentiment, earnings and institutional ownership.

In the previous week, Danaher had 9 more articles in the media than Crane. MarketBeat recorded 30 mentions for Danaher and 21 mentions for Crane. Danaher's average media sentiment score of 1.07 beat Crane's score of 0.40 indicating that Danaher is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Danaher
21 Very Positive mention(s)
4 Positive mention(s)
1 Neutral mention(s)
2 Negative mention(s)
2 Very Negative mention(s)
Positive
Crane
13 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
2 Very Negative mention(s)
Neutral

Danaher has a net margin of 14.89% compared to Crane's net margin of 13.10%. Crane's return on equity of 24.45% beat Danaher's return on equity.

Company Net Margins Return on Equity Return on Assets
Danaher14.89% 10.91% 6.94%
Crane 13.10%24.45%10.14%

Danaher has a beta of 0.81, suggesting that its stock price is 19% less volatile than the S&P 500. Comparatively, Crane has a beta of 1.15, suggesting that its stock price is 15% more volatile than the S&P 500.

79.1% of Danaher shares are held by institutional investors. Comparatively, 75.1% of Crane shares are held by institutional investors. 10.8% of Danaher shares are held by insiders. Comparatively, 2.1% of Crane shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Danaher has higher revenue and earnings than Crane. Crane is trading at a lower price-to-earnings ratio than Danaher, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Danaher$24.78B5.01$3.61B$5.1733.91
Crane$2.44B4.14$401.10M$5.5631.56

Danaher presently has a consensus target price of $240.70, suggesting a potential upside of 37.31%. Crane has a consensus target price of $226.33, suggesting a potential upside of 28.97%. Given Danaher's higher possible upside, analysts clearly believe Danaher is more favorable than Crane.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Danaher
0 Sell rating(s)
3 Hold rating(s)
18 Buy rating(s)
0 Strong Buy rating(s)
2.86
Crane
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
2 Strong Buy rating(s)
3.25

Danaher pays an annual dividend of $1.60 per share and has a dividend yield of 0.9%. Crane pays an annual dividend of $1.02 per share and has a dividend yield of 0.6%. Danaher pays out 30.9% of its earnings in the form of a dividend. Crane pays out 18.3% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Danaher has increased its dividend for 2 consecutive years and Crane has increased its dividend for 3 consecutive years.

Summary

Danaher beats Crane on 12 of the 20 factors compared between the two stocks.

How does Danaher compare to Carlisle Companies?

Carlisle Companies (NYSE:CSL) and Danaher (NYSE:DHR) are both large-cap industrial conglomerates companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, dividends, media sentiment, institutional ownership, risk and earnings.

89.5% of Carlisle Companies shares are owned by institutional investors. Comparatively, 79.1% of Danaher shares are owned by institutional investors. 1.3% of Carlisle Companies shares are owned by insiders. Comparatively, 10.8% of Danaher shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Danaher had 14 more articles in the media than Carlisle Companies. MarketBeat recorded 30 mentions for Danaher and 16 mentions for Carlisle Companies. Danaher's average media sentiment score of 1.07 beat Carlisle Companies' score of 1.06 indicating that Danaher is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Carlisle Companies
7 Very Positive mention(s)
4 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Danaher
21 Very Positive mention(s)
4 Positive mention(s)
1 Neutral mention(s)
2 Negative mention(s)
2 Very Negative mention(s)
Positive

Danaher has a net margin of 14.89% compared to Carlisle Companies' net margin of 14.57%. Carlisle Companies' return on equity of 43.78% beat Danaher's return on equity.

Company Net Margins Return on Equity Return on Assets
Carlisle Companies14.57% 43.78% 13.66%
Danaher 14.89%10.91%6.94%

Carlisle Companies has a beta of 0.88, meaning that its stock price is 12% less volatile than the S&P 500. Comparatively, Danaher has a beta of 0.81, meaning that its stock price is 19% less volatile than the S&P 500.

Danaher has higher revenue and earnings than Carlisle Companies. Carlisle Companies is trading at a lower price-to-earnings ratio than Danaher, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Carlisle Companies$5.02B2.87$740.70M$17.0120.96
Danaher$24.78B5.01$3.61B$5.1733.91

Carlisle Companies presently has a consensus price target of $405.00, suggesting a potential upside of 13.58%. Danaher has a consensus price target of $240.70, suggesting a potential upside of 37.31%. Given Danaher's stronger consensus rating and higher probable upside, analysts clearly believe Danaher is more favorable than Carlisle Companies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Carlisle Companies
0 Sell rating(s)
6 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.45
Danaher
0 Sell rating(s)
3 Hold rating(s)
18 Buy rating(s)
0 Strong Buy rating(s)
2.86

Carlisle Companies pays an annual dividend of $4.40 per share and has a dividend yield of 1.2%. Danaher pays an annual dividend of $1.60 per share and has a dividend yield of 0.9%. Carlisle Companies pays out 25.9% of its earnings in the form of a dividend. Danaher pays out 30.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Carlisle Companies has raised its dividend for 48 consecutive years and Danaher has raised its dividend for 2 consecutive years. Carlisle Companies is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Summary

Danaher beats Carlisle Companies on 11 of the 19 factors compared between the two stocks.

Get Danaher News Delivered to You Automatically

Sign up to receive the latest news and ratings for DHR and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DHR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

DHR vs. The Competition

MetricDanaherMedical Services IndustryMedical SectorNYSE Exchange
Market Cap$124.07B$8.11B$6.24B$22.98B
Dividend Yield0.89%2.18%2.73%4.03%
P/E Ratio33.9124.7729.0628.58
Price / Sales5.0117.82475.4323.44
Price / Cash15.4113.2327.6219.03
Price / Book2.364.969.694.68
Net Income$3.61B$183.43M$3.55B$1.07B
7 Day Performance-2.19%0.44%1.46%0.83%
1 Month Performance-8.31%5.42%5.35%6.48%
1 Year Performance-11.23%0.48%33.88%31.62%

Danaher Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
DHR
Danaher
4.7753 of 5 stars
$175.20
+0.7%
$240.70
+37.4%
N/A$123.95B$24.78B33.8760,000
RGEN
Repligen
3.8273 of 5 stars
$118.31
+4.6%
$170.25
+43.9%
N/A$6.67B$738.26M139.192,000
TECH
Bio-Techne
4.2687 of 5 stars
$55.32
+6.5%
$72.77
+31.5%
N/A$8.65B$1.22B108.473,100
A
Agilent Technologies
4.9784 of 5 stars
$115.57
+3.8%
$163.71
+41.7%
N/A$32.66B$7.07B25.5118,100
CR
Crane
4.7635 of 5 stars
$177.68
+0.8%
$226.33
+27.4%
N/A$10.25B$2.44B23.5311,000

Related Companies and Tools


This page (NYSE:DHR) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners